APLS
Apellis Pharmaceuticals, Inc.
No data for this timeframe.
Vol
Inst. Holders50 funds
Inst. Value$3.7B
Inst. Activity32 buys / 18 sells
SEC Reports5
Recent Activity
May 26, 2026
SEC
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective
15-12G — Impact 6/10
May 14, 2026
SEC
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May
25-NSE — Impact 2/10
May 14, 2026
SEC
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merge
8-K — Impact 8/10
May 14, 2026
Insider
WHEELER CRAIG A disposed of 24,444 shares
Director
May 14, 2026
Insider
WHEELER CRAIG A disposed of 15,110 shares
Director
May 14, 2026
Insider
Baumal Caroline disposed of 82,500 shares
Chief Medical Officer
Inst.
BlackRock, Inc. — DOUBLED
13,536,964 shares ($544.6M)
Inst.
STATE STREET CORP — ADD
6,844,990 shares ($275.4M)
Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$40.92 (Oct 2024)
Current $41.03
Low $40.00
Median $41.00
High $41.00
13 analysts
$40.00
$41.00
Analyst Ratings
3Strong Buy
5Buy
19Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 16, 2024 | Scotiabank | INITIATE | Sector Perform |
| Oct 16, 2024 | William Blair | INITIATE | Outperform |
| Sep 24, 2024 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Sep 23, 2024 | Baird | MAINTAIN | Outperform → Outperform |
| Sep 20, 2024 | Mizuho | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.32 ▲ +3.5% | $-0.49 — $-0.16 | 4% YoY | 8 |
| Next Q | $-0.28 ▼ -6.2% | $-0.60 — $-0.10 | -117% YoY | 8 |
| Current FY | $-1.17 ▼ -4.1% | $-2.19 — $-0.38 | -687% YoY | 8 |
| Next FY | $-0.31 ▼ -28.7% | $-2.02 — $0.68 | 73% YoY | 7 |
Latest Reports
NEUTRAL
15-12G
6/10
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective
May 26, 2026
NEUTRAL
25-NSE
2/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Clear Street Group Inc. | — | — |
| BlackRock, Inc. | $544.6M | DOUBLED |
| Avoro Capital Advisors LLC | $491.7M | — |
| MORGAN STANLEY | $404.0M | — |
| STATE STREET CORP | $275.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | WHEELER CRAIG | U | $0.00 |
| May 14, 2026 | WHEELER CRAIG | D | $0.00 |
| May 14, 2026 | Baumal Caroline | D | $0.00 |
| May 14, 2026 | Walbert Keli | D | $0.00 |
| May 14, 2026 | Chan Gerald | U | $0.00 |
50 institutional holders with $3.7B total value (93,390,987 shares) as of 2026-Q1. Top holders: Clear, BlackRock,, Avoro. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Clear Street Group Inc. | 350,000 | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 13,536,964 | $544.6M | 14.6% | DOUBLED +116.2% |
| 3 | Avoro Capital Advisors LLC | 12,222,222 | $491.7M | 13.2% | — |
| 4 | MORGAN STANLEY | 10,042,399 | $404.0M | 10.8% | — |
| 5 | STATE STREET CORP | 6,844,990 | $275.4M | 7.4% | ADD +48.4% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,404,559 | $217.4M | 5.8% | — |
| 7 | Pentwater Capital Management LP | 5,250,000 | $211.2M | 5.7% | NEW |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4,768,944 | $191.9M | 5.2% | — |
| 9 | Point72 Asset Management, L.P. | 4,183,918 | $168.3M | 4.5% | DOUBLED +600.0% |
| 10 | RTW INVESTMENTS, LP | 3,685,045 | $148.2M | 4.0% | TRIM -51.9% |
| 11 | GOLDMAN SACHS GROUP INC | 1,980,144 | $79.7M | 2.1% | — |
| 12 | BALYASNY ASSET MANAGEMENT L.P. | 1,917,501 | $77.1M | 2.1% | DOUBLED +2844.0% |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,338,995 | $53.7M | 1.4% | DOUBLED +640.1% |
| 14 | TORONTO DOMINION BANK | 1,236,436 | $49.7M | 1.3% | NEW |
| 15 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1,202,100 | $48.4M | 1.3% | NEW |
| 16 | BANK OF AMERICA CORP /DE/ | 1,190,864 | $47.9M | 1.3% | — |
| 17 | Hudson Bay Capital Management LP | 1,190,416 | $47.9M | 1.3% | — |
| 18 | FIL Ltd | 1,140,000 | $45.9M | 1.2% | NEW |
| 19 | SOROS FUND MANAGEMENT LLC | 1,056,000 | $42.5M | 1.1% | NEW |
| 20 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 1,013,500 | $40.8M | 1.1% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 6,260,113 | 13,536,964 | +116.2% | $544.6M | 2026-Q1 |
| STATE STREET CORP | ADD | 4,613,446 | 6,844,990 | +48.4% | $275.4M | 2026-Q1 |
| Pentwater Capital Management LP | NEW | — | 5,250,000 | — | $211.2M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 597,672 | 4,183,918 | +600.0% | $168.3M | 2026-Q1 |
| RTW INVESTMENTS, LP | TRIM | 7,666,764 | 3,685,045 | -51.9% | $148.2M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 65,133 | 1,917,501 | +2844.0% | $77.1M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 180,925 | 1,338,995 | +640.1% | $53.7M | 2026-Q1 |
| TORONTO DOMINION BANK | NEW | — | 1,236,436 | — | $49.7M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | NEW | — | 1,202,100 | — | $48.4M | 2026-Q1 |
| FIL Ltd | NEW | — | 1,140,000 | — | $45.9M | 2026-Q1 |
| SOROS FUND MANAGEMENT LLC | NEW | — | 1,056,000 | — | $42.5M | 2026-Q1 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | NEW | — | 1,013,500 | — | $40.8M | 2026-Q1 |
| Woodline Partners LP | ADD | 542,981 | 976,175 | +79.8% | $39.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 633,058 | 935,958 | +47.8% | $37.7M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 495,947 | 903,637 | +82.2% | $36.4M | 2026-Q1 |
| Magnetar Financial LLC | NEW | — | 869,229 | — | $35.0M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 215,000 | 650,000 | +202.3% | $26.1M | 2026-Q1 |
| Invesco Ltd. | ADD | 225,976 | 437,868 | +93.8% | $17.6M | 2026-Q1 |
| LMR Partners LLP | NEW | — | 403,622 | — | $16.2M | 2026-Q1 |
| Verition Fund Management LLC | NEW | — | 400,000 | — | $16.1M | 2026-Q1 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | NEW | — | 366,674 | — | $14.8M | 2026-Q1 |
| GABELLI FUNDS LLC | NEW | — | 321,200 | — | $12.9M | 2026-Q1 |
| RHUMBLINE ADVISERS | DOUBLED | 116,917 | 275,540 | +135.7% | $11.1M | 2026-Q1 |
| CAPSTONE INVESTMENT ADVISORS, LLC | NEW | — | 250,000 | — | $10.1M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | NEAR_EXIT | 12,721,352 | 249,635 | -98.0% | $10.0M | 2026-Q1 |
15 unique insiders with 50 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | WHEELER CRAIG A | Director | U | 24,444 | — | — |
| May 14, 2026 | WHEELER CRAIG A | Director | D | 15,110 | — | — |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | D | 82,500 | — | — |
| May 14, 2026 | Walbert Keli | Director | D | 8,332 | — | — |
| May 14, 2026 | Chan Gerald | Director | U | 25,666 | — | — |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | U | 86,525 | — | — |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | AWARD | 41,250 | — | — |
| May 14, 2026 | Baumal Caroline | Chief Medical Officer | D | 41,250 | — | — |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | U | 425,968 | — | — |
| May 14, 2026 | Chan Gerald | Director | D | 3,062 | — | — |
| May 14, 2026 | Machiels Alec | Director | U | 384,989 | — | — |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | AWARD | 143,750 | — | — |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | D | 143,750 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | U | 144,517 | — | — |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | D | 100,538 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | AWARD | 41,250 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 41,250 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 82,500 | — | — |
| May 14, 2026 | WHEELER CRAIG A | Director | D | 28,195 | — | — |
| May 14, 2026 | Boucher Kelley | Chief People Officer | U | 127,804 | — | — |
| May 14, 2026 | Boucher Kelley | Chief People Officer | AWARD | 15,073 | — | — |
| May 14, 2026 | Boucher Kelley | Chief People Officer | D | 15,073 | — | — |
| May 14, 2026 | Boucher Kelley | Chief People Officer | D | 32,976 | — | — |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | U | 25,666 | — | — |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | D | 3,062 | — | — |
| May 14, 2026 | O'Brien Stephanie Monaghan | Director | D | 17,580 | — | — |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | U | 114,591 | — | — |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | AWARD | 41,250 | — | — |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | D | 41,250 | — | — |
| May 14, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | D | 82,500 | — | — |
| May 14, 2026 | Walbert Keli | Director | U | 17,051 | — | — |
| May 14, 2026 | Walbert Keli | Director | D | 14,684 | — | — |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | U | 116,338 | — | — |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | AWARD | 22,610 | — | — |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | D | 22,610 | — | — |
| May 14, 2026 | Nicholson Nur | Chief Technical Officer | D | 82,500 | — | — |
| May 14, 2026 | Chan Gerald | Director | D | 17,580 | — | — |
| May 14, 2026 | Chopas James George | VP/Chief Accounting Officer | AWARD | 5,625 | — | — |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | U | 1,177,222 | — | — |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | AWARD | 41,250 | — | — |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | D | 41,250 | — | — |
| May 14, 2026 | Deschatelets Pascal | Chief Scientific Officer | D | 108,622 | — | — |
| May 14, 2026 | Machiels Alec | Director | D | 3,062 | — | — |
| May 14, 2026 | Machiels Alec | Director | D | 17,580 | — | — |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | U | 140,945 | — | — |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | AWARD | 41,250 | — | — |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | D | 41,250 | — | — |
| May 14, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | D | 232,903 | — | — |
| May 14, 2026 | FONTEYNE PAUL R. | Director | U | 30,666 | — | — |
| May 14, 2026 | FONTEYNE PAUL R. | Director | D | 3,062 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
15-12G
6/10
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting ob
May 26, 2026
NEUTRAL
25-NSE
2/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registra
May 14, 2026
BULLISH
8-K
8/10
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer
May 14, 2026
NEUTRAL
8-K
2/10
Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection w
May 4, 2026
MIXED
INST-CLUSTER
6/10
In Q4 2024, Apellis Pharmaceuticals (APLS) saw a mixed institutional cluster: two mega-passive firms
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Oct 2024): 30% buy across 27 analysts — 3 strong buy, 5 buy, 19 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$40.92 mean target (Oct 2024)
$40.00 Low
$41.00 High
| Metric | Value |
|---|---|
| Current Price | $41.03 |
| Target Low | $40.00 |
| Target Mean | $40.92 |
| Target Median | $41.00 |
| Target High | $41.00 |
| # Analysts | 13 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.32 | $-0.49 | $-0.16 | 3.8% | +3.5% | 0↑ 2↓ | $0.2B | 17.6% | 8 |
| Next Q 2026-09-30 |
$-0.28 | $-0.60 | $-0.10 | -116.8% | -6.2% | 1↑ 1↓ | $0.2B | -52.2% | 8 |
| Current FY 2026-12-31 |
$-1.17 | $-2.19 | $-0.38 | -686.9% | -4.1% | 2↑ 1↓ | $0.9B | -7.9% | 8 |
| Next FY 2027-12-31 |
$-0.31 | $-2.02 | $0.68 | 73.2% | -28.7% | 3↑ 2↓ | $1.0B | 11.2% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.318 | |
| 7d ago | $-0.329 | +0.012 |
| 30d ago | $-0.329 | +0.012 |
| 60d ago | $-0.309 | -0.008 |
| 90d ago | $-0.353 | +0.035 |
16 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | INITIATE | — | Sector Perform |
| Oct 16, 2024 | William Blair | INITIATE | — | Outperform |
| Sep 24, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Sep 23, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Sep 20, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Sep 20, 2024 | Needham | REITERATE | Buy | Buy |
| Sep 13, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 13, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 9, 2024 | UBS | MAINTAIN | Buy | Buy |
| Aug 9, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Aug 9, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Aug 9, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Aug 9, 2024 | Needham | REITERATE | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | Needham | REITERATE | Buy | Buy |
| Jul 31, 2024 | Jefferies | MAINTAIN | Buy | Buy |
| Jul 26, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jul 23, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jul 17, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Jun 28, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| May 31, 2024 | Piper Sandler | INITIATE | — | Neutral |
| May 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 23, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| May 8, 2024 | Citigroup | MAINTAIN | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 8, 2024 | UBS | MAINTAIN | Buy | Buy |
| May 8, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 29, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Apr 26, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 25, 2024 | Needham | REITERATE | Buy | Buy |
| Apr 17, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2024 | Needham | REITERATE | Buy | Buy |
| Mar 27, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Mar 6, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 4, 2024 | UBS | MAINTAIN | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 28, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 16, 2024 | Mizuho | MAINTAIN | Neutral | Neutral |
| Feb 6, 2024 | Baird | REITERATE | Outperform | Outperform |
| Feb 5, 2024 | Jefferies | UPGRADE | Hold | Buy |
| Jan 30, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 24, 2024 | Needham | MAINTAIN | Buy | Buy |
| Jan 17, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jan 17, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 12, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jan 11, 2024 | Raymond James | MAINTAIN | Strong Buy | Strong Buy |
| Jan 9, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 15, 2023 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| May 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Apr 1, 2026 | 3 | 9 | 15 | 0 | 0 | 44% | |
| Mar 1, 2026 | 8 | 12 | 8 | 1 | 0 | 69% | |
| Feb 1, 2026 | 8 | 12 | 7 | 1 | 0 | 71% | |
| Jan 1, 2026 | 7 | 12 | 8 | 1 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
Market Close Report - Tuesday, March 31, 2026
▲ 1
💬 0
⚡ 0.5
Jun 5, 2026
Clinical Trial
Pegcetacoplan Long Term Safety and Efficacy Extension Study
Phase Phase 3 — COMPLETED
May 11, 2026
dark_pool
Dark Pool: APLS — 13.4M shares, 34,348 trades
Week starting 2026-05-11. Total ATS volume: 13,393,774 shares across 34,348 trades.
May 5, 2026
earnings_calendar
APLS Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
short_interest
FTD: APLS — 33,636 shares ($1.4M) failed to deliver
Settlement: 20260504, Price: $40.96, FTD Value: $1,377,730.56, APELLIS PHARMACEUTICALS INC CO
May 4, 2026
dark_pool
Dark Pool: APLS — 4.4M shares, 25,576 trades
Week starting 2026-05-04. Total ATS volume: 4,377,894 shares across 25,576 trades.
Apr 30, 2026
earnings_calendar
APLS Q1 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_interest
FTD: APLS — 28,566 shares ($1.2M) failed to deliver
Settlement: 20260430, Price: $40.95, FTD Value: $1,169,777.7, APELLIS PHARMACEUTICALS INC CO
Apr 29, 2026
short_interest
FTD: APLS — 555,013 shares ($22.7M) failed to deliver
Settlement: 20260429, Price: $40.99, FTD Value: $22,749,982.87, APELLIS PHARMACEUTICALS INC CO
Apr 27, 2026
dark_pool
Dark Pool: APLS — 1.9M shares, 22,743 trades
Week starting 2026-04-27. Total ATS volume: 1,928,228 shares across 22,743 trades.
Apr 24, 2026
short_volume
Short Volume: APLS — 55.0% short (0.3M / 0.6M)
Short: 317,489 | Exempt: 0 | TRF Vol: 577,020 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_interest
FTD: APLS — 39,752 shares ($1.6M) failed to deliver
Settlement: 20260422, Price: $40.94, FTD Value: $1,627,446.88, APELLIS PHARMACEUTICALS INC CO
Apr 21, 2026
Clinical Trial
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Phase Phase 2 — COMPLETED
Apr 20, 2026
short_interest
FTD: APLS — 14,078 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $40.90, FTD Value: $575,790.2, APELLIS PHARMACEUTICALS INC CO
Apr 20, 2026
dark_pool
Dark Pool: APLS — 2.4M shares, 21,808 trades
Week starting 2026-04-20. Total ATS volume: 2,399,324 shares across 21,808 trades.
Apr 13, 2026
dark_pool
Dark Pool: APLS — 3.9M shares, 30,619 trades
Week starting 2026-04-13. Total ATS volume: 3,920,540 shares across 30,619 trades.
Apr 13, 2026
short_volume
Short Volume: APLS — 61.5% short (2.1M / 3.3M)
Short: 2,059,937 | Exempt: 134 | TRF Vol: 3,347,152 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_interest
FTD: APLS — 22,198 shares ($0.9M) failed to deliver
Settlement: 20260407, Price: $40.63, FTD Value: $901,904.74, APELLIS PHARMACEUTICALS INC CO